ID: ALA388350

Max Phase: Preclinical

Molecular Formula: C20H29N5O4

Molecular Weight: 403.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)c1nc(C[C@H](NC(=O)[C@H]2CCC(=O)C2)C(=O)N2CCC[C@H]2C(N)=O)c[nH]1

Standard InChI:  InChI=1S/C20H29N5O4/c1-11(2)18-22-10-13(23-18)9-15(24-19(28)12-5-6-14(26)8-12)20(29)25-7-3-4-16(25)17(21)27/h10-12,15-16H,3-9H2,1-2H3,(H2,21,27)(H,22,23)(H,24,28)/t12-,15-,16-/m0/s1

Standard InChI Key:  HFMCVIZOMVYWSL-RCBQFDQVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 403.48

Molecular Weight (Monoisotopic): 403.2220

AlogP: 0.41

#Rotatable Bonds: 7

Polar Surface Area: 138.25

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.40

CX Basic pKa: 6.84

CX LogP: -0.41

CX LogD: -0.51

Aromatic Rings: 1

Heavy Atoms: 29

QED Weighted: 0.61

Np Likeness Score: -0.41

References

1. Kaur N, Monga V, Lu X, Gershengorn MC, Jain R..  (2007)  Modifications of the pyroglutamic acid and histidine residues in thyrotropin-releasing hormone (TRH) yield analogs with selectivity for TRH receptor type 2 over type 1.,  15  (1): [PMID:17035026] [10.1016/j.bmc.2006.09.045]

Source

Source(1):

• Scientific Literature